Abstract:Abstract Chronic systemic inflammation increases the risk of neurodegeneration, but the mechanisms remain unclear. Part of the challenge in reaching a nuanced understanding is the presence of multiple risk factors that interact to potentiate adverse consequences. To address modifiable risk factors and mitigate downstream effects, it is necessary, although difficult, to tease apart the contribution of an individual risk factor by accounting for concurrent factors such as advanced age, cardiovascular risk, and genetic predisposition. Using a case-control design, we investigated the influence of asthma, a highly prevalent chronic inflammatory disease of the airways, on brain health in participants recruited to the Wisconsin Alzheimer’s Disease Research Center (31 asthma patients, 186 non-asthma controls, aged 45–90 years, 62.2% female, 92.2% cognitively unimpaired), a sample enriched for parental history of Alzheimer’s disease. Asthma status was determined using detailed prescription information. We employed multi-shell diffusion weighted imaging scans and the three-compartment neurite orientation dispersion and density imaging model to assess white and gray matter microstructure. We used cerebrospinal fluid biomarkers to examine evidence of Alzheimer’s disease pathology, glial activation, neuroinflammation and neurodegeneration. We evaluated cognitive changes over time using a preclinical Alzheimer cognitive composite. Using permutation analysis of linear models, we examined the moderating influence of asthma on relationships between diffusion imaging metrics, CSF biomarkers, and cognitive decline, controlling for age, sex, and cognitive status. We ran additional models controlling for cardiovascular risk and genetic risk of Alzheimer’s disease, defined as a carrier of at least one apolipoprotein E (APOE) ε4 allele. Relative to controls, greater Alzheimer’s disease pathology (lower amyloid-β42/amyloid-β40, higher phosphorylated-tau-181) and synaptic degeneration (neurogranin) biomarker concentrations were associated with more adverse white matter metrics (e.g. lower neurite density, higher mean diffusivity) in patients with asthma. Higher concentrations of the pleiotropic cytokine IL-6 and the glial marker S100B were associated with more salubrious white matter metrics in asthma, but not in controls. The adverse effects of age on white matter integrity were accelerated in asthma. Finally, we found evidence that in asthma, relative to controls, deterioration in white and gray matter microstructure was associated with accelerated cognitive decline. Taken together, our findings suggest that asthma accelerates white and gray matter microstructural changes associated with aging and increasing neuropathology, that in turn, are associated with more rapid cognitive decline. Effective asthma control, on the other hand, may be protective and slow progression of cognitive symptoms.

Systemic Inflammation in Asthma: What are the risks and impacts outside the airway?

Asthma and comorbidities: recent advances

Molecular pathways underlying lung-brain axis signaling in asthma: Relevance for psychopathology and neuroinflammation

Microbes little helpers and suppliers for therapeutic asthma approaches

Obesity, Inflammation, and Severe Asthma: an Update

Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease

Immunology of asthma and chronic obstructive pulmonary disease

Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline

Autophagy and inflammation in chronic respiratory disease

Asthma and hypertension: the role of airway inflammation

Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model

Airway Remodeling in Asthma: Mechanisms, Diagnosis, Treatment, and Future Directions

The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma

Type 2 inflammation in asthma and other airway diseases

Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation

Prevalence, Risk Factors and Multimorbidity

Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?

Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation

Innate players in Th2 and non-Th2 asthma: emerging roles for the epithelial cell, mast cell, and monocyte/macrophage network